China’s biotechnology stocks have shaken off a four-year slump to be among the hottest performers in Asia this year and funds ...

Recent federal actions could derail decades of progress. Meanwhile China has prioritized investment in biotech.

China has leaped from fast follower to global pioneer in drug discovery and development. We believe that Chinese companies ...

For all the attention on U.S.-China AI competition, new studies point to China’s rapid rise in biotechnology, especially for ...

U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data ...

This is where Hong Kong's unique identity shines. As both part of China and a globally connected offshore market, it occupies ...

I believe that the major risk to ZLAB’s growth is the fact that all its current products are commercialized in China alone, and this is likely to continue in the near-term. The Chinese biotech ...

China's biotechnology sector is experiencing notable growth, with the ChinaAMC Hang Seng Biotech ETF, tracking the Hang Seng ...

Overall, this saw China-based biotech firms increase their market ... However, if the Chinese biotech sector is going to continue its growth trajectory, certain other aspects beyond investment ...

Shares to fall as Middle East tensions escalate; oil spikes above $US78.32; gold climbs. ASIC investigate ASX; Adnoc agrees ...

After delivering strong sales growth last year and with more expansion in mind, CDMO giant Wuxi Biologics is breaking ground ...

The recent uptick in the performance of A-share and Hong Kong-listed biotech stocks, particularly those related to innovative drugs, mirrors the trend toward a faster internationalization of China's ...